Amidst the ever-increasing corona infection in the country, everyone is waiting for its vaccine. In addition to Russia and China leading in the vaccine race, many countries including India are very close to success on the vaccine. There are three vaccines going forward in the country, one of which is 'Covaxin' being developed by ICMR and Bharat Biotech. The launch date of 'COVAXIN', like Serum India's vaccine 'Kovishield' and Zydus Cadila's vaccine 'Zaykov-D', is not yet set. But this vaccine is in the final stages of its trial. The final phase of the trial is going to be conducted in two more cities in the country.
There is good news from Uttar Pradesh about this country-based vaccine 'COVAXIN'. Human trials of the third phase of this vaccine will begin in two major cities here. It has been allowed. The good news has come from UP. The country has high hopes for this corona vaccine being developed by Bharat Biotech. Its positive results have been revealed in the trial to date.
The vaccine trial is being conducted in Lucknow and Gorakhpur. Additional Chief Secretary (Health), Uttar Pradesh, Amit Mohan Prasad says that the Phase-3 trial of COVAXIN, a Kovid vaccine being developed by Bharat Biotech, has been approved. BRD Medical College will lead the trial in October along with SGPGI in Lucknow and Bharat Biotech in Gorakhpur.
According to the news, India will be in touch with Dr. Rajneesh Dubey, Additional Chief Secretary of Medical Education during the third phase trial of Biotech Covaxine. During this time, they will have to be informed about the vaccine trial activities from time to time. India will be able to use the biotech vaccine on the people of Lucknow and Gorakhpur.
It is known that Bharat Biotech Company has entered into an agreement with the University of Washington for the Corona vaccine. The company has signed a licensing agreement with Washington University's School of Medicine in St. Louis for a single-dose vaccine for the corona - chimp adenovirus. According to reports, the company will have the right to vaccinate in all markets except the US, Japan, and Europe.